Special Issue "Melanoma and Neoplasms of Skin"
A special issue of Healthcare (ISSN 2227-9032).
Deadline for manuscript submissions: closed (30 September 2013)
Dr. Robert Loewe
Skin and Endothelium Research Division, Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria
Interests: melanoma; metastasis; microenvironment; tumor lymphangiogenesis; melanoma models; tumor biology; rare skin tumors; dermatopathology
All malignant skin neoplasms together account for more than 50% of all human cancers. Cutaneous squamous cell carcinoma and basal cell carcinoma (non-melanoma skin cancers), are the most numerous of skin tumors, with incidence rates of up to 90 per 100.000. Although the mortality of these tumors is clearly much lower than of melanoma, patients often have to suffer from multiple, sometimes even mutilating, therapeutic procedures.
In 2008, more than 20.000 patients died of cutaneous melanoma in Europe. Nowadays, incidence rates increased to 20 patients per 100,000. For a long period, the only option for successful therapy consisted of early surgery. Recently, new therapeutic options have become to be available, starting to give hope for patients.
Merkel cell carcinoma, cutaneous lymphoma or cutaneous sarcoma are rare but highly malignant skin neoplasms. Patients affected by these tumors often face diagnostic problems and the lack of available therapy.
Because of their mortality, the number of affected patients, increasing incidence rates, as well as therapeutic considerations, skin neoplasms represent an important socioeconomic health problem.
Dr. Robert Loewe
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- non-melanoma skin cancer
- Merkel cell carcinoma
- cutaneous lymphoma
- skin neoplasm
- non-melanoma skin cancer
Healthcare 2013, 1(1), 64-83; doi:10.3390/healthcare1010064
Received: 6 August 2013; in revised form: 30 September 2013 / Accepted: 30 September 2013 / Published: 17 October 2013| Download PDF Full-text (4490 KB)
Review: B-Mode Ultrasound Imaging, Doppler Imaging, and Real-Time Elastography in Cutaneous Malignant Melanoma and Lymph Node Metastases
Healthcare 2013, 1(1), 84-95; doi:10.3390/healthcare1010084
Received: 24 July 2013; in revised form: 27 September 2013 / Accepted: 17 October 2013 / Published: 23 October 2013| Download PDF Full-text (3089 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Article
Title: Detection and Discrimination of Non-Melanoma Skin Cancer by Multimodal Imaging
Authors: S. Heuke 1, N. Vogler 1, T. Meyer 1, D. Akimov 1, F. Kluschke 3, H.-J. Röwert-Huber 3, J. Lademann 3, B. Dietzek 1,2, J. Popp 1,2
Affiliation: 1 Institute of Photonic Technology Jena (IPHT), Albert-Einstein-Straße 9, 07745 Jena, Germany; 2 Institute of Physical Chemistry and Abbe Center of Photonics, Friedrich-Schiller-University Jena, Helmholtzweg 4, 07743 Jena, Germany; 3 Charité - Universitätsmedizin Berlin, Department of Dermatology, Venerology and Allergology, Charitéplatz 1, 10117 Berlin, Germany; E-Mail: firstname.lastname@example.org
Abstract: In this contribution ex vivo sections of non-melanoma skin cancer (NMSC) are investigated using non-linear optical microscopy. The combination of coherent anti-Stokes Raman scattering (CARS), two photon excited fluorescence (TPEF) and second harmonic generation (SHG)—referred to as multimodal imaging—yields detailed information of the spatial distribution of lipids, the skin’s endogenous fluorophores and collagen fibers. Thus, complementary information of different levels of tissue organization is provided, which are molecular groups, fluorophores and supramolecular structures. Moreover, hallmarks of cancer like the tumor-stroma interaction, the bioenergetics as well as the fat metabolism can be evaluated. Therefore, non-linear microscopy provides means for the localization, classification and prognosis of NMSC.
Type of Paper: Review
Title: Established and emerging biomarkers in cutaneous malignant melanoma
Authors: Stamatina Verykiou 1, Robert Ellis 1,2 and Penny Lovat 1
Affiliation: 1 Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; 2 The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, TS4 3BW, UK; E-Mail: email@example.com; firstname.lastname@example.org; email@example.com
Abstract: In an era of personalised medicine, disease specific biomarkers play a major role in the stratification of high-risk patient groups. Cutaneous malignant melanoma is the most aggressive type of skin cancer. Despite having an excellent prognosis when diagnosed at the initial stages, metastatic disease carries significant overall mortality. Biomarkers aim not only to identify high risk patients but also provide potential therapeutic targets for differing patient subgroups. Furthermore, accessibility in malignant melanoma, unlike other cancers provides the unique opportunity to study patient derived tissue of differing disease stage. Over the past decade there have been major advances in targeted therapies, providing new avenues and hope to patients with this devastating disease. This review will focus on most up to date histological, serological and molecular biomarkers in malignant melanoma.
Type of paper: Article
Title: Update on the surgical management of cutaneous melanoma
Authors: Alex K. Wong
Affiliation: Institute for Genetic Medicine, Division of Plastic and Reconstructive Surgery, Keck School of Medicine of USC, 1510 San Pablo Street, Suite 415, Los Angeles, CA 90033, USA; E-Mail: Alex.Wong@med.usc.edu
Abstract: Melanoma is responsible for the majority of deaths related to skin caner and according to a World Health Organization report, approximately 48,000 melanoma related deaths occur each year. If detected early, complete surgical excision can be curative, however due to the intrinsic biology of melanoma, it is a highly malignant tumor type with high potential for regional and distant metastasis. This article will review and update the reader on the surgical management of primary melanoma including surgical margins, Moh's micrographic surgery for melanoma in situ, sentinel lymph node biopsy, and lymphadenectomy. Surgery for metastatic lesions in conjunction with systemic medical therapy will also be discussed.
Type of Paper: Review
Title: Interferons in melanoma
Authors: Romina Lenci, Rajiv Kumar
Affiliation: Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany; E-Mail: firstname.lastname@example.org
Abstract: Malignant melanoma is a tumor that arises from transformation of melanocytes, which are dendritic cells located at the basal layer of the epidermis with a specific function of producing pigmentation substance melanin. Melanoma can disseminate rapidly by local extension through lymphatics and/or by hematogenous routes to distant sites. While melanoma only represents about 3% of all skin cancers, it is the most aggressive and lethal form of skin cancer because it accounts for the highest death rate. Metastasized melanoma has proven to be largely resistant to current therapeutic approaches. More personalized targeted therapies for metastatic melanoma are emerging. Inhibitors of mutant BRAF, such as Vemurafenib and Dabrafenib, have been shown to inhibit tumor growth and increases patients' overall survival. Melanoma is a highly immunogenic tumor. This fact has been supported by observation of spontaneous remissions of growing melanomas, presence of tumor-infiltrated lymphocytes which, as well as the development of vitiligo, was correlated with a better survival in melanoma patients. Taking into account the capabilities of immune system to participate in lysis of tumor cells, immunotherapy is becoming one of the standard treatments for this disease. Medications such as interferon have been shown to improve the patient's prognosis despite side effects.
Type of Paper: Article
Title: Melanoma of the Hand: Current Practice and New Frontiers
Authors: J. Brad Turner, M.D.; Brian Rinker, M.D.
Affiliation: Resident and Associate Professor of Plastic and Reconstructive Surgery, Medical Directory of Hand Surgery Service, University of Kentucky Department of Plastic and Reconstructive Surgery, 740 South Limestone, Lexington, KY 40536, USA; E-Mail: email@example.com
Abstract: Melanoma of the hand represents a complicated clinical entity. Anatomic features of the hand create challenges in successful management of melanoma not encountered elsewhere in the body. The objectives of this article are to outline current standards for managing melanoma of the hand including diagnosis, surgical, chemotherapeutic and radiation management. Particular emphasis will be placed in currently debated topics of the role of sentinel lymph node biopsy, the role of Mohs micrographic surgery, tissue sparing management of subungual melanoma, and the consideration of melanoma of the hand as a distinct entity based on clinical and molecular studies.
Last update: 26 June 2013